Cited by 250Immunotoxicology and immune responsesMonoclonal and Polyclonal Antibodies ResearchAnimal testing and alternatives

The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.

Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies

Open access

Brennan, Frank R., Morton, Laura Dill, Spindeldreher, Sebastian, Kiessling, Andrea, Allenspach, Roy, Hey, Adam, Müller, Patrick, Frings, Werner, Sims, Jennifer·2010·mAbs

DOI 10.4161/mabs.2.3.11782PMC PMC2881251

Open this paper in CoChat — free account Open PDF

Abstract

Most therapeutic monoclonal antibodies (mAbs) licensed for human use or in clinical development are indicated for treatment of patients with cancer and inflammatory/autoimmune disease and as such, are designed to directly interact with the immune system. A major hurdle for the development and early clinical investigation of many of these immunomodulatory mAbs is their inherent risk for adverse immune-mediated drug reactions in humans such as infusion reactions, cytokine storms, immunosuppression and autoimmunity. A thorough understanding of the immunopharmacology of a mAb in humans and animals is required to both anticipate the clinical risk of adverse immunotoxicological events and to select a safe starting dose for first-in-human (FIH) clinical studies. This review summarizes the most common adverse immunotoxicological events occurring in humans with immunomodulatory mAbs and outlines non-clinical strategies to define their immunopharmacology and assess their immunotoxic potential, as well as reduce the risk of immunotoxicity through rational mAb design. Tests to assess the relative risk of mAb candidates for cytokine release syndrome, innate immune system (dendritic cell) activation and immunogenicity in humans are also described. The importance of selecting a relevant and sensitive toxicity species for human safety assessment in which the immunopharmacology of the mAb is similar to that expected in humans is highlighted, as is the importance of understanding the limitations of the species selected for human safety assessment and supplementation of in vivo safety assessment with appropriate in vitro human assays. A tiered approach to assess effects on immune status, immune function and risk of infection and cancer, governed by the mechanism of action and structural features of the mAb, is described. Finally, the use of immunopharmacology and immunotoxicity data in determining a minimum anticipated biologic effect Level (MABEL) and in the selection of safe human starting dose is discussed.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.4161/mabs.2.3.11782

Cites

115 of 115 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Fcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164
Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial
Weinblatt, M. E., Keystone, E. C., Furst, D. E., Moreland, L. W., Weisman, M. H., Birbara, C. A., Teoh, L. S., Fischkoff, S. A., & Chartash, E. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10697 · Cited by 1,754
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
Chung, C. H., Mirakhur, B., Chan, E., Le, Q.-T., Berlin, J., Morse, M., Murphy, B. A., Satinover, S. M., Hosen, J., Mauro, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074943 · Cited by 1,521
NOD/SCID/γcnull mouse: an excellent recipient mouse model for engraftment of human cells
Ito, M., Hiramatsu, H., Kobayashi, K., Suzue, K., Kawahata, M., Hioki, K., Ueyama, Y., Koyanagi, Y., Sugamura, K., Tsuji, K., et al. (2002) · Blood · doi:10.1182/blood-2001-12-0207 · Cited by 1,483
Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses
Bruhns, P., Iannascoli, B., England, P., Mancardi, D. A., Fernandez, N., Jorieux, S., & Daëron, M. (2009) · Blood · doi:10.1182/blood-2008-09-179754 · Cited by 1,479
Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant Erythropoietin
Casadevall, N., Nataf, J., Viron, B. M., Kolta, A. M., Kiladjian, J., Martin-Dupont, P., Michaud, P. A., Papo, T., Ugo, V., Teyssandier, I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011931 · Cited by 1,244
Development of a Human Adaptive Immune System in Cord Blood Cell-Transplanted Mice
Traggiai, E., Chicha, L., Mazzucchelli, L., Bronz, L., Piffaretti, J.-C., Lanzavecchia, A., & Manz, M. G. (2004) · Science · doi:10.1126/science.1093933 · Cited by 989
Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices
Sturniolo, T., Bono, E. B., Ding, J., Raddrizzani, L., Tuereci, O., Şahin, U., Braxenthaler, M., Gallazzi, F., Protti, M. P., Sinigaglia, F., et al. (1999) · Nature Biotechnology · doi:10.1038/9858 · Cited by 743
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis
Yang, J. C., Hughes, M., Kammula, U., Royal, R., Sherry, R. M., Topalian, S. L., Suri, K. B., Levy, C., Allen, T., Mavroukakis, S., et al. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318156e47e · Cited by 697
Thrombocytopenia caused by the development of antibodies to thrombopoietin
Li, J., Yang, C., Xia, Y., Bertino, A. M., Glaspy, J. A., Roberts, M., & Kuter, D. J. (2001) · Blood · doi:10.1182/blood.v98.12.3241 · Cited by 682
The Linkage of Innate to Adaptive Immunity via Maturing Dendritic Cells In Vivo Requires CD40 Ligation in Addition to Antigen Presentation and CD80/86 Costimulation
Fujii, S., Liu, K., Smith, C., Bonito, A., & Steinman, R. (2004) · Journal of Experimental Medicine · doi:10.1084/jem.20040317 · Cited by 647
Immunostimulatory monoclonal antibodies for cancer therapy
Melero, I., Hervás‐Stubbs, S., Glennie, M. J., Pardoll, D. M., & Chen, L. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2051 · Cited by 634
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed
van de Putte, L. B. A., Atkins, C., Malaise, M., Sany, J., Russell, A. S., van Riel, P. L. C. M., Settas, L., Bijlsma, J. W. J., TODESCO, S., Dougados, M., et al. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.013052 · Cited by 619
Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method
Peters, B., & Sette, A. (2005) · BMC Bioinformatics · doi:10.1186/1471-2105-6-132 · Cited by 514
Tolerability and safety of rituximab (MabThera®)
Kimby, E. K. (2005) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2005.05.007 · Cited by 472
Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis
Coles, A. J., Wing, M., Smith, S., Coraddu, F., Greer, S., Taylor, C., Weetman, A., Hale, G., Chatterjee, V. K., Waldmann, H., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)02429-0 · Cited by 453
Progressive Multifocal Leukoencephalopathy in Patients on Immunomodulatory Therapies
Major, E. O. (2009) · Annual Review of Medicine · doi:10.1146/annurev.med.080708.082655 · Cited by 437
Immune surveillance in multiple sclerosis patients treated with natalizumab
Stüve, O., Marra, C. M., Jerome, K. R., Cook, L., Cravens, P. D., Cepok, S., Frohman, E. M., Phillips, J. T., Arendt, G., Hemmer, B., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20858 · Cited by 434
Triggering of OX40 (CD134) on CD4+CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR
Valzasina, B., Guiducci, C., Dislich, H., Killeen, N. P., Weinberg, A. D., & Colombo, M. P. (2005) · Blood · doi:10.1182/blood-2004-07-2959 · Cited by 428
TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells.
Geissmann, F., Revy, P., Régnault, A., Lepelletier, Y., Dy, M., Brousse, N., Amigorena, S., Hermine, O., & Durandy, A. (1999) · PubMed · Cited by 373
Preclinical safety evaluation of biotechnology-derived pharmaceuticals
Cavagnaro, J. A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd822 · Cited by 340
Species differences in the structure and function of the immune system
Haley, P. J. (2003) · Toxicology · doi:10.1016/s0300-483x(03)00043-x · Cited by 336
TGF-β1 Prevents the Noncognate Maturation of Human Dendritic Langerhans Cells
Geissmann, F., Revy, P., Régnault, A., Lepelletier, Y., Dy, M., Brousse, N., Amigorena, S., Hermine, O., & Durandy, A. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.8.4567 · Cited by 333
Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products.
Koren, E., Smith, H. W., Shores, E., Shankar, G., Finco-Kent, D., Rup, B., Barrett, Y., Devanarayan, V., Gorovits, B., Gupta, S., et al. (2008) · JIM - Journal of Immunological Methods · doi:10.1016/j.jim.2008.01.001 · Cited by 332
Risk Assessment in Immunotoxicology II. Relationships between Immune and Host Resistance Tests
Luster, M. I. (1993) · Fundamental and Applied Toxicology · doi:10.1006/faat.1993.1074 · Cited by 329
Toll-like receptors (TLRs) and Nod-like receptors (NLRs) in inflammatory disorders
Fukata, M., Vamadevan, A. S., & Abreu, M. T. (2009) · Seminars in Immunology · doi:10.1016/j.smim.2009.06.005 · Cited by 326
"Cytokine Storm" in the Phase I Trial of Monoclonal Antibody TGN1412: Better Understanding the Causes to Improve PreClinical Testing of Immunotherapeutics
Stebbings, R., Findlay, L., Edwards, C., Eastwood, D., Bird, C., North, D., Mistry, Y., Dilger, P., Liefooghe, E., Cludts, I., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.5.3325 · Cited by 316 · cited 2×
“In subsequent experiments TGN1412 did stimulate pro-inflammatory cytokine release in either PBMC or 1:5 diluted whole blood test systems if the antibody was immobilized by air drying to plastic or anti-Fc antibody capture, or if the antibody was added in aqueous phase in the presence of endothelial cells.(52) Addition…”
BackgroundMethod
Antibody therapeutics:
Jefferis, R. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.9.1401 · Cited by 301
Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo
Labrijn, A. F., Buijsse, A. O., van den Bremer, E. T. J., Verwilligen, A., Bleeker, W. K., Thorpe, S. J., Killestein, J., Polman, C. H., Aalberse, R. C., Schuurman, J., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1553 · Cited by 297
An interspecies comparison of placental antibody transfer: New insights into developmental toxicity testing of monoclonal antibodies
Pentšuk, N., & van der Laan, J. W. (2009) · Birth Defects Research Part B Developmental and Reproductive Toxicology · doi:10.1002/bdrb.20201 · Cited by 292
Improved prediction of MHC class I and class II epitopes using a novel Gibbs sampling approach
Nielsen, M., Lundegaard, C., Worning, P., Sylvester‐Hvid, C., Lamberth, K., Buus, S., Brunak, S., & Lund, O. (2004) · Bioinformatics · doi:10.1093/bioinformatics/bth100 · Cited by 279
IMMUNOLOGICAL RELATIONSHIP BETWEEN THE MOTHER AND THE FETUS
Szekeres‐Barthó, J. (2002) · International Reviews of Immunology · doi:10.1080/08830180215017 · Cited by 255
Antigen-Antibody Immune Complexes Empower Dendritic Cells to Efficiently Prime Specific CD8+ CTL Responses In Vivo
Schuurhuis, D. H., Ioan‐Facsinay, A., Nagelkerken, B., Schip, J. J. V. D. P.-V., Sedlik, C., Melief, C. J. M., Verbeek, J. S., & OSSENDORP, F. A. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.5.2240 · Cited by 238
Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use (1997)
&NA;, &. (1997) · Journal of Immunotherapy · doi:10.1097/00002371-199705000-00007 · Cited by 232
An HLA-DR1 Transgene Confers Susceptibility to Collagen-induced Arthritis Elicited with Human Type II Collagen
Rosloniec, E. F., Brand, D. D., Myers, L. K., Whittington, K. B., Gumanovskaya, M. L., Zaller, D. M., Woods, A., Altmann, D. M., Stuart, J. M., & Kang, A. H. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.6.1113 · Cited by 222
Progressive Multifocal Leukoencephalopathy after Natalizumab Monotherapy
Lindå, H., von Heijne, A., Major, E. O., Ryschkewitsch, C. F., Berg, J., Olsson, T. P., & Martin, C. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810316 · Cited by 218
Siglecs in innate immunity
Crocker, P. R. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.03.003 · Cited by 206
Loss of Siglec expression on T lymphocytes during human evolution
Nguyen, D. H., Hurtado-Ziola, N., Gagneux, P., & Varki, A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510484103 · Cited by 204
Structural characterization of a human Fc fragment engineered for lack of effector functions
Oganesyan, V., Gao, C., Shirinian, L., Wu, H., & Dall’Acqua, W. F. (2008) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444908007877 · Cited by 199
Commentary on the EMA Guideline on strategies to identify and mitigate risks for first‐in‐human and early clinical trials with investigational medicinal products
van Gerven, J., & Bonelli, M. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13550 · Cited by 162
STP Position Paper: Best Practice Guideline for the Routine Pathology Evaluation of the Immune System
STP Immunotoxicology Working Group, Haley, P., Perry, R. J., Ennulat, D., Frame, S. R., Johnson, C., Lapointe, J. ‐., Nyska, A., Snyder, P. W., Walker, D., et al. (2005) · Toxicologic Pathology · doi:10.1080/01926230590934304 · Cited by 160
International Conference on Harmonisation; Guidance on M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals; availability. Notice.
(2010) · PubMed · Cited by 150
The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies
Muller, P. Y., Milton, M., Lloyd, P. M., Sims, J., & Brennan, F. R. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.10.013 · Cited by 146
Self-citation
Structural Characterization and Immunogenicity in Wild-Type and Immune Tolerant Mice of Degraded Recombinant Human Interferon Alpha2b
Hermeling, S., Caetano, L. A., Damen, M. J. A., Slijper, M., Schellekens, H., Crommelin, D. J. A., & Jiskoot, W. (2005) · Pharmaceutical Research · doi:10.1007/s11095-005-8177-9 · Cited by 144
Immunotoxicity of monoclonal antibodies
Descotes, J. (2009) · mAbs · doi:10.4161/mabs.1.2.7909 · Cited by 140
Histopathologic Approaches to Detect Changes Indicative of Immunotoxicity
Kuper, C. F., Harleman, J. H., Richter-Reichelm, H. B., & Vos, J. G. (2000) · Toxicologic Pathology · doi:10.1177/019262330002800317 · Cited by 140
Forecasting the cytokine storm following systemic interleukin (IL)-2 administration
Panelli, M. C., White, R., Foster, M., Martin, B., Wang, E., Smith, K., & Marincola, F. M. (2004) · Journal of Translational Medicine · doi:10.1186/1479-5876-2-17 · Cited by 139
Antigen‐Presenting Cells and Materno‐Fetal Tolerance: An Emerging Role for Dendritic Cells
Laškarin, G., Kämmerer, U., Rukavina, D., Thomson, A. W., Fernández, N., & Blois, S. M. (2007) · American Journal of Reproductive Immunology · doi:10.1111/j.1600-0897.2007.00511.x · Cited by 124
Infections Associated with Tumor Necrosis Factor‐α Antagonists
Rychly, D. J., & DiPiro, J. T. (2005) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.2005.25.9.1181 · Cited by 121
Using an analogous monoclonal antibody to evaluate the reproductive and chronic toxicity potential for a humanized anti-TNFa monoclonal antibody
Treacy, G. B. (2000) · Human & Experimental Toxicology · doi:10.1191/096032700678815765 · Cited by 110
Lupus-Like Syndrome Attributable to Anti—Tumor Necrosis Factor α Therapy in 14 Patients During an 8-Year Period at Mayo Clinic
Wetter, D. A., & Davis, M. D. P. (2009) · Mayo Clinic Proceedings · doi:10.4065/84.11.979 · Cited by 108
Effects of an Anti‐TNF‐α Monoclonal Antibody, Administered Throughout Pregnancy and Lactation, on the Development of the Macaque Immune System
Martin, P. L., Oneda, S., & Treacy, G. (2007) · American Journal of Reproductive Immunology · doi:10.1111/j.1600-0897.2007.00499.x · Cited by 108
Safety Assessment and Dose Selection for First-in-Human Clinical Trials With Immunomodulatory Monoclonal Antibodies
Muller, P., & Brennan, F. R. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.273 · Cited by 107
Self-citation
B-Cell-Targeted Therapy for Systemic Lupus Erythematosus
Sabahi, R., & Anolik, J. H. (2006) · Drugs · doi:10.2165/00003495-200666150-00004 · Cited by 106
What’s So Special about the Developing Immune System?
Burns‐Naas, L. A., Hastings, K. L., Ladics, G. S., Makris, S. L., Parker, G. A., & Holsapple, M. P. (2008) · International Journal of Toxicology · doi:10.1080/10915810801978110 · Cited by 105
IgG Fc Receptor III Homologues in Nonhuman Primate Species: Genetic Characterization and Ligand Interactions
Rogers, K. A., Scinicariello, F., & Attanasio, R. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.6.3848 · Cited by 102
Lupus-Like Syndrome Attributable to Anti—Tumor Necrosis Factor α Therapy in 14 Patients During an 8-Year Period at Mayo Clinic
Wetter, D. A., & Davis, M. D. P. (2009) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60668-x · Cited by 100
Integrated studies of biology: multiplexed imaging assays from molecules to man and back
Eliceiri, K. W., & Contag, C. H. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.04.001 · Cited by 99
Preclinical development of monoclonal antibodies
Chapman, K. L., Pullen, N., Coney, L., Dempster, M., Andrews, L., Bajramovic, J. J., Baldrick, P., Buckley, L. A., Jacobs, A., Hale, G., et al. (2009) · mAbs · doi:10.4161/mabs.1.5.9676 · Cited by 99
The Trifunctional Antibody Ertumaxomab Destroys Tumor Cells That Express Low Levels of Human Epidermal Growth Factor Receptor 2
Jäger, M., Schoberth, A., Ruf, P., Hess, J., & Lindhofer, H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2861 · Cited by 94
Use of pharmacokinetic/ pharmacodynamic modelling for starting dose selection in first‐in‐human trials of high‐risk biologics
Agoram, B. M. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2008.03297.x · Cited by 85
Natalizumab and Progressive Multifocal Leukoencephalopathy
Adelman, B., Sandrock, A. W., & Panzara, M. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmc055235 · Cited by 82
On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development
Lowe, P. J., Hijazi, Y., Luttringer, O., Yin, H., Sarangapani, R., & Howard, D. (2007) · Xenobiotica · doi:10.1080/00498250701648008 · Cited by 82
Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer--identification, prevention, and management.
Kang, S. P., & Saif, M. W. (2007) · PubMed · Cited by 82
Genomic analysis of the Tapasin gene, located close to the TAP loci in the MHC
Herberg, J. A., SGOUROS, J. G., Jones, T., Copeman, J. B., Humphray, S., Sheer, D., Cresswell, P., Beck, S., & Trowsdale, J. (1998) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199802)28:02 · Cited by 81
A vector driving the expression of foreign cDNAs in the MHC class II-positive cells of transgenic mice
Kouskoff, V., Fehling, H. J., LeMeur, M., Benoist, C. O., & Mathis, D. J. (1993) · Journal of Immunological Methods · doi:10.1016/0022-1759(93)90370-m · Cited by 80
Developmental toxicity testing of monoclonal antibodies: An enhanced pre- and postnatal study design option
Stewart, J. (2009) · Reproductive Toxicology · doi:10.1016/j.reprotox.2009.04.002 · Cited by 80
Anti-CD40 agonist antibodies: Preclinical and clinical experience
Khalil, M., & Vonderheide, R. H. (2007) · Update on Cancer Therapeutics · doi:10.1016/j.uct.2007.06.001 · Cited by 78
REVIEW ARTICLE: NK Cell Tolerance and the Maternal–Fetal Interface
Riley, J. K., & Yokoyama, W. M. (2008) · American Journal of Reproductive Immunology · doi:10.1111/j.1600-0897.2008.00593.x · Cited by 77
Evaluation of a surrogate antibody for preclinical safety testing of an anti-CD11a monoclonal antibody
Clarke, J. B., Leach, W., Pippig, S. D., Joshi, A., Wu, B. M., House, R. V., & Beyer, J. C. (2004) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2004.06.007 · Cited by 77
Clinical immunotoxicity of therapeutic proteins
Descotes, J., & Gouraud, A. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250802525496 · Cited by 76
Preclinical development of keliximab, a Primatized™ anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model and safety studies
Bugelskil, P. J., Herzykl, D. J., Rehm, S., Harmsen, A. G., Gore, E., Williams, D. M., Maleeff, B. E., Badger, A. M., Truneh, A., O'Brien, S., et al. (2000) · Human & Experimental Toxicology · doi:10.1191/096032700678815783 · Cited by 75
Developmental immunotoxicology (DIT): windows of vulnerability, immune dysfunction and safety assessment
Dietert, R. R. (2008) · Journal of Immunotoxicology · doi:10.1080/15476910802483324 · Cited by 75
Peripheral blood CD4+CD8+ lymphocytes in cynomolgus monkeys are of resting memory T lineage
Akari, H. (1997) · International Immunology · doi:10.1093/intimm/9.4.591 · Cited by 73
Negative and positive selection by HLA-DR3(DRw17) molecules in transgenic mice
Strau\, G., Vignali, D. A. A., Sch�nrich, G., & H�mmerling, G. (1994) · Immunogenetics · doi:10.1007/bf00188172 · Cited by 71
Risk of High-Grade Skin Rash in Cancer Patients Treated with Cetuximab – an Antibody against Epidermal Growth Factor Receptor: Systemic Review and Meta-Analysis
Su, X. Q., Lacouture, M. E., Jia, Y., & Wu, S. (2009) · Oncology · doi:10.1159/000229752 · Cited by 66
Review of Human DC Subtypes
Ju, X., Clark, G. J., & Hart, D. N. J. (2006) · Methods in molecular biology · doi:10.1007/978-1-60761-421-0_1 · Cited by 65
Monoclonal Antibody First Dose Cytokine Release Syndromes–Mechanisms and Prediction
Wing, M. G. (2008) · Journal of Immunotoxicology · doi:10.1080/15476910801897433 · Cited by 64
The Accuracy of Extended Histopathology to Detect Immunotoxic Chemicals
Germolec, D. R. (2004) · Toxicological Sciences · doi:10.1093/toxsci/kfh271 · Cited by 60
Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies
Lynch, C. M., Hart, B. W., & Grewal, I. S. (2009) · mAbs · doi:10.4161/mabs.1.1.7377 · Cited by 59
Preclinical Safety Evaluation of Biopharmaceuticals
(2007) · Wiley eBooks · doi:10.1002/9780470292549 · Cited by 59
Whole blood cytokine response as a measure of immunotoxicity
Langezaal, I., Coecke, S., & Härtung, T. (2001) · Toxicology in Vitro · doi:10.1016/s0887-2333(01)00028-5 · Cited by 58
Natalizumab and progressive multifocal leucoencephalopathy
Berger, J. R. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.058404 · Cited by 57
New Approaches to Prediction of Immune Responses to Therapeutic Proteins during Preclinical Development
Perry, L., Jones, T. D., & Baker, M. (2008) · Drugs in R&D · doi:10.2165/0126839-200809060-00004 · Cited by 50
Evaluation of the Immuno-Stimulatory Potential of Stopper Extractables and Leachables by Using Dendritic Cells as Readout
Mueller, R., Karle, A. C., Vogt, A. B., Kropshofer, H., Ross, A., Mäder, K., & Mahler, H. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21672 · Cited by 47
The Role of the CTLA4 Blockade in the Treatment of Malignant Melanoma
Cranmer, L. D., & Hersh, E. M. (2007) · Cancer Investigation · doi:10.1080/07357900701522315 · Cited by 47
Human leukocyte antigen-DRB1∗1502 (DR2Dw12) transgene reduces incidence and severity of arthritis in mice
González-Gay, M. Á., Zanelli, E. H., Khare, S. D., Krco, C. J., Zhou, P., Inoko, H., Griffiths, M. M., Luthra, H. S., & David, C. S. (1996) · Human Immunology · doi:10.1016/0198-8859(96)00123-1 · Cited by 46
Testing Human Biologicals in Animal Host Resistance Models
Burleson, G. R., & BURLESON, F. G. (2008) · Journal of Immunotoxicology · doi:10.1080/15476910801897557 · Cited by 45
A HUMANIZED ANTI-CD3 ANTIBODY, HuM291, WITH LOW MITOGENIC ACTIVITY, MEDIATES COMPLETE AND REVERSIBLE T-CELL DEPLETION IN CHIMPANZEES
Hsu, D., Shi, J. D., Homola, M. E., Rowell, T. J., Moran, J., Levitt, D., Druilhet, B., Chinn, J., Bullock, C., & Klingbeil, C. (1999) · Transplantation · doi:10.1097/00007890-199908270-00018 · Cited by 45
The status of biologic therapies in the treatment of moderate to severe psoriasis.
Menter, A. (2009) · PubMed · Cited by 44
Alemtuzumab in Chronic Lymphocytic Leukemia
Fraser, G. A. M., Smith, C. A., Imrie, K., Meyer, R. M., & The Hematology Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care (2007) · Current Oncology · doi:10.3747/co.2007.118 · Cited by 41
Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-α antagonists
Isaacs, J. D. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903379494 · Cited by 41
Influenza virus host resistance model
Burleson, G. R., & BURLESON, F. G. (2006) · Methods · doi:10.1016/j.ymeth.2006.09.007 · Cited by 40
The state of the art: immune-mediated mechanisms of monoclonal antibodies in cancer therapy
Griggs, J. J., & Zinkewich-Péotti, K. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605349 · Cited by 35
Adverse Consequences of Immunostimulation
Ponce, R. A. (2008) · Journal of Immunotoxicology · doi:10.1080/15476910801897920 · Cited by 35
Biologic Therapies in Clinical Development for the Treatment of Rheumatoid Arthritis
Genovese, M. C. (2005) · JCR Journal of Clinical Rheumatology · doi:10.1097/01.rhu.0000166625.65114.5f · Cited by 34
Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues
Bria, E., Cuppone, F., Milella, M., Verma, S., Carlini, P., Nisticò, C., Vaccaro, V., Rossi, A., Tonini, G., Cognetti, F., et al. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14728220802517935 · Cited by 33
Reproductive/Developmental Toxicity Assessment of Biopharmaceuticals in Nonhuman Primates
Weinbauer, G. F., Frings, W., Fuchs, A., Niehaus, M., & Osterburg, I. (2007) · doi:10.1002/9780470292549.ch18 · Cited by 33
Self-citation
Novel targeted therapies for autoimmunity
Clair, E. W. S. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.09.008 · Cited by 31
Eculizumab: A novel therapy for paroxysmal nocturnal hemoglobinuria
Zaręba, K. M. (2007) · Drugs of today · doi:10.1358/dot.2007.43.8.1130446 · Cited by 31
Recombinant antibodies for cancer therapy
Deonarain, M. P. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.8.1123 · Cited by 29
Investigational Immunotherapeutics for B-Cell Malignancies
Quintás‐Cardama, A., Wierda, W. G., & O'Brien, S. M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8254 · Cited by 27
Anchor profiles of HLA‐specific peptides: Analysis by a novel affinity scoring method and experimental validation
Desmet, J., Meersseman, G., Boutonnet, N. S., Pletinckx, J., Clercq, K. D., Debulpaep, M., Braeckman, T., & Lasters, I. (2004) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.20302 · Cited by 27
Immunotoxicity Evaluation by Immune Function Tests: Focus on the T-Dependent Antibody Response (TDAR) [Overview of a Workshop Session at the 45th Annual Meeting of the Society of Toxicology (SOT) March 5–9, 2006 San Diego, CA]
Herzyk, D. J., & Holsapple, M. P. (2007) · Journal of Immunotoxicology · doi:10.1080/15476910701337308 · Cited by 24
Monoclonal antibodies in the therapy of multiple sclerosis
Rommer, P. S., Stüve, O., Goertsches, R. H., Mix, E., & Zettl, U. K. (2008) · Journal of Neurology · doi:10.1007/s00415-008-6006-x · Cited by 23
Essentials for starting a pediatric clinical study (3): Dynamic changes in early development of immune system in macaque monkeys -The significance from standpoint of preclinical toxicity test using nonhuman primates-
Terao, K. (2009) · The Journal of Toxicological Sciences · doi:10.2131/jts.34.sp321 · Cited by 13
Bacterial host resistance models in the evaluation of immunotoxicity
Cohen, M. D. (2006) · Methods · doi:10.1016/j.ymeth.2006.08.010 · Cited by 10
Assessment of Autoimmunity and Hypersensitivity
Descotes, J., & Vial, T. (2007) · doi:10.1002/9780470292549.ch21 · Cited by 4
Assessment of Autoimmunity and Hypersensitivity
Descotes, J., & Vial, T. (2010) · Pharmaceutical Sciences Encyclopedia · doi:10.1002/9780470571224.pse180 · Cited by 2
Naturally Processed Self‐peptides of MHC Molecules
Kropshofer, H., & Spindeldreher, S. (2005) · doi:10.1002/3527607021.ch6 · Cited by 2
Self-citation
Dynamic changes in early development of immune system in macaque monkeys : The significance from standpoint of preclinical toxicity test using nonhuman primates
Terao, K. (2009) · The Journal of Toxicological Sciences · Cited by 2
Antigen-presenting cells
(2004) · Springer eBooks · doi:10.1007/3-540-29662-x_231 · Cited by 1
Untitled work
Rodriguez-Palmero, M. (1999) · doi:10.1002/(sici)1521-4141(199912)29:12

Flagged first, then by citations

Research works printed but not linked: 6

Menter A, 2009, Cutis, 84, 14
CDER/FDA, 2005, Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers
EMEA/CHMP, 2007, Guideline on Strategies to Identify and Mitigate Risks for First-In-Human Clinical Trials with Investigational Medicinal Products
Kang SP, 2007, J Support Oncol, 5, 451
Bugelski PJ, 2008, Slide Presentation, FDA Immunotoxicology Symposium, Cytokine Release: What Does It Mean?
Strauss G, 1994, Immunogenetics, 40, 104

Sorted by citations

Phagocytosis checkpoints as new targets for cancer immunotherapy
Feng, M., Jiang, W., Kim, B. Y. S., Zhang, C. C., Fu, Y., & Weissman, I. L. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0183-z · Cited by 937
Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cells
Zhu, X., Badawi, M. A., Pomeroy, S. M., Sutaria, D. S., Xie, Z., Baek, A., Jiang, J., Elgamal, O. A., Mo, X. M., Perle, K. L., et al. (2017) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2017.1324730 · Cited by 599
Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines
Dobrovolskaia, M. A., & McNeil, S. E. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.05.025 · Cited by 324
Clinical cancer immunotherapy: Current progress and prospects
Liu, C., Yang, M., Zhang, D., Chen, M., & Zhu, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.961805 · Cited by 261
Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum
Wang, S.-L., Ohrmund, L., Hauenstein, S. I., Salbato, J., Reddy, R., Monk, P., Lockton, S., LING, N. C., & Singh, S. (2012) · Journal of Immunological Methods · doi:10.1016/j.jim.2012.06.002 · Cited by 210

See all 250

Authors: Brennan, F. R., Morton, L. D., Spindeldreher, S., Kiessling, A., Allenspach, R., Hey, A., Müller, P., Frings, W., & Sims, J.
Affiliations: Novartis (Switzerland) (CH)
Corresponding author: Brennan, Frank R.
ORCID: Spindeldreher, Sebastian
Hey, Adam
Frings, Werner
Venue: mAbs
Publisher: Informa UK Limited
Published: 2010-05
Volume: 2
Issue: 3
Pages: 233-255
ISSN: 1942-0862 (ISSN-L)
1942-0870
DOI: 10.4161/mabs.2.3.11782
PMC: PMC2881251
OpenAlex: W2044692977
Cited by: 250
References: 115
Citations by year: 2026: 13 · 2025: 12 · 2024: 21 · 2023: 13 · 2022: 14 · 2021: 9 · 2020: 13 · 2019: 15 · 2018: 18 · 2017: 23 · 2016: 16 · 2015: 19 · 2014: 19 · 2013: 22 · 2012: 14
FWCI: 1.15
Type: journal article
Language: en
Open access: gold
doi.org
Locations: mAbs (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
Keywords: immunotoxicity, immunopharmacology, cytokine release syndrome, dendritic cell activation, immunogenicity, first-in-human dose selection, immune-related adverse events
MeSH terms: Animals, Antibodies, Monoclonal, Autoimmune Diseases, Clinical Trials as Topic, Dendritic Cells, Drug Evaluation, Preclinical, Humans, Immune System, Neoplasms, Cytokines, Guidelines as Topic, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks